CRL2LRR-1 Targets a CDK Inhibitor for Cell Cycle Control in C. elegans and Actin-Based Motility Regulation in Human Cells  by Starostina, Natalia G. et al.
Developmental Cell
ArticleCRL2LRR-1 Targets a CDK Inhibitor for Cell Cycle
Control in C. elegans and Actin-Based Motility
Regulation in Human Cells
Natalia G. Starostina,1,* Jennifer M. Simpliciano,1 Michael A. McGuirk,1 and Edward T. Kipreos1,*
1Department of Cellular Biology, University of Georgia, Athens, GA 30602, USA
*Correspondence: ngs@uga.edu (N.G.S.), ekipreos@cb.uga.edu (E.T.K.)
DOI 10.1016/j.devcel.2010.10.013SUMMARY
The Cip/Kip CDK inhibitor (CKI) p21Cip1/WAF1 has a
critical role in the nucleus to limit cell proliferation
by inhibiting CDK-cyclin complexes. In contrast,
cytoplasmic p21 regulates cell survival and the actin
cytoskeleton. These divergent functions for p21 in
different cellular compartments suggest the neces-
sity for complex regulation. In this study, we identify
the CRL2LRR-1 ubiquitin ligase as a conserved regu-
lator of Cip/Kip CKIs that promotes the degradation
of C. elegans CKI-1 and human p21. The nematode
CRL2LRR-1 complex negatively regulates nuclear
CKI-1 levels to ensure G1-phase cell cycle progres-
sion in germ cells. In contrast, human CRL2LRR1
targets cytoplasmic p21, acting as a critical regulator
of cell motility that promotes a nonmotile stationary
cell state by preventing p21 from inhibiting the
Rho/ROCK/LIMK pathway. Inactivation of human
CRL2LRR1 leads to the activation of the actin-depoly-
merizing protein cofilin, dramatic reorganization of
the actin cytoskeleton, and increased cell motility.
INTRODUCTION
Cell migration underpins fundamental processes in animal devel-
opment and homeostasis. Defects in cell movement are associ-
ated with pathological processes such as vascular disease and
tumor metastasis (Jaffe and Hall, 2005; Narumiya et al., 2009;
Ridley et al., 2003; Shimokawa and Rashid, 2007). Cell migration
involves the remodeling of the actin cytoskeleton, which occurs
through the coordination of two opposing activities: actin
depolymerization mediated by ADF/cofilin proteins, and actin
polymerization catalyzed by actin nucleating and polymeriza-
tion-promoting factors, such as Arp2/3 and formins (Jaffe and
Hall, 2005; Ridley, 2006).
Small GTPases of the Rho family, Rho, Rac, and Cdc42, are
key regulators of the actin cytoskeleton (Jaffe and Hall, 2005;
Ridley et al., 2003). Cdc42 establishes cell polarity and is respon-
sible for the formation of filopodia. Rac is required for the forma-
tion of lamellipodia and promotes cell spreading. RhoA, B, and
C, collectively referred to here as Rho, induce the formation of
actin stress fibers and focal adhesions, in part through theDevelopmeactivation of formins (Jaffe and Hall, 2005; Ridley, 2006). In non-
migrating cells, Rho maintains cell shape and the attachment to
the substrate (Nobes and Hall, 1999). Rho regulates the actin
cytoskeleton in part by activating the Rho-associated kinases
ROCK I and II (referred to here as ROCK) (Narumiya et al.,
2009), which in turn affects a number of ROCK effectors, of
which a central effector is LIM kinase (LIMK) (Schmandke and
Strittmatter, 2007). LIMK is activated by ROCK and inhibits the
actin-depolymerizing protein cofilin via the phosphorylation of
cofilin on its serine 3 residue (Schmandke and Strittmatter,
2007). Cofilin plays a key role in cytoskeleton dynamics and
cell migration by stimulating the severing and depolymerization
of actin filaments, and, under certain conditions, can nucleate
actin filaments (Bernstein and Bamburg, 2010). Cofilin’s activity
is defined by its phosphorylation status, and the increased
activity of the unphosphorylated cofilin is associated with
enhanced cell movement and cancer metastasis (Bernstein
and Bamburg, 2010; Ono, 2007; Wang et al., 2007).
High Rho activity promotes strong adhesion to the substrate
and inhibits cell migration (Nobes and Hall, 1999; Pellegrin and
Mellor, 2007). Cell movement is associated with the gradient-
wise downregulation of Rho and the activation of Rac at the
leading edge, while Rho activity is required for tail retraction in
the migrating cell (Ridley et al., 2003). The Rho-family GTPases
thus require tight spatial and temporal regulation for proper actin
remodeling as cells transition between stationary and motile
states.
Members of the mammalian Cip/Kip family of cyclin-depen-
dent kinase (CDK)-inhibitors (CKIs), p21Cip1, p27Kip1, and
p57Kip2, have the well-known function to regulate the cell cycle
by inhibiting a broad range of CDK-cyclin complexes (Sherr
and Roberts, 1999). Cip/Kip CKIs bind CDK-cyclin complexes
in the nucleus, and elevated nuclear CKI levels inhibit cell division
(Abukhdeir and Park, 2008; Bornstein et al., 2003; Gu et al., 1993;
Harper et al., 1993). The CKIs function as tumor suppressors,
with their inactivation increasing CDK-cyclin activity that drives
cell proliferation (Abukhdeir and Park, 2008; Besson et al.,
2004a). However, elevated levels of cytoplasmic p21 and p27
have been observed in a number of human cancers and are
associated with high tumor grade and poor prognosis (Abukh-
deir and Park, 2008; Besson et al., 2004a, 2008; Blagosklonny,
2002). This contradiction between the tumor suppressor function
of the CKIs and their elevated cytoplasmic levels in aggressive
cancers suggested that the CKIs have an alternate function in
the cytoplasm. Twomajor functions have been assigned to cyto-
plasmic CKIs: anti-apoptotic activity and the regulation of thental Cell 19, 753–764, November 16, 2010 ª2010 Elsevier Inc. 753
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CRL2LRR-1 Controls Cell Cycle and Cell Motilityactin cytoskeleton (Besson et al., 2008). In particular, p21, p27,
and p57 each negatively regulate the Rho/ROCK/LIMK pathway
in the cytoplasm. p27 inhibits Rho, p21 inhibits ROCK, and p57
inactivates LIMK (Besson et al., 2004b; Lee and Helfman,
2004; McAllister et al., 2003; Tanaka et al., 2002; Yokoo et al.,
2003).
The accumulation of cytoplasmic p21 and p27 is linked to the
oncogenic transformation of cells by activated Ras, HER2/neu,
or ErbB2 (Lee and Helfman, 2004; Liu et al., 2000; Xia et al.,
2004). Cytoplasmic p21 levels are also elevated during develop-
mental events, including the differentiation of monocytes and
fibroblasts as well as axon regeneration and neurite extension
(Asada et al., 1999; Lee and Helfman, 2004; Manapov et al.,
2005; Tanaka et al., 2002). These findings suggest that the cyto-
plasmic localization of CKIs is under complex regulation;
however, the mechanisms of such regulation are poorly
understood.
In this study, we identify a ubiquitin ligase (E3) that specifically
regulates cytoplasmic p21 levels in human cells—the cullin
2-RING ubiquitin ligase (CRL2) complex. CRL2 complexes are
multisubunit E3s that contain five components: the scaffold
protein CUL2; a RING H2 protein (Rbx1/Roc1) that binds the
ubiquitin-conjugating enzyme; the adaptor Elongin C that is in
complex with Elongin B; and a variable substrate-recognition
subunit (SRS) that links to the complex through interaction with
Elongin C (Bosu and Kipreos, 2008). The SRS determines the
substrate specificity of the CRL complex, and thereby the
associated cellular functions.
Here we show that the leucine-rich repeat protein LRR-1 func-
tions as the SRS for a CRL2LRR-1 complex that targets the
degradation of the Cip/Kip CDK-inhibitor CKI-1 in C. elegans to
promote cell cycle progression in germ cells. We further show
that the orthologous human CRL2LRR1 complex has a conserved
function in human cells, where it mediates the degradation of the
CDK-inhibitor p21Cip1. However, in human cells, the degradation
of p21 by CRL2LRR1 does not appreciably affect cell cycle
progression. Rather, human CRL2LRR1 targets the degradation
of p21 in the cytoplasm to prevent the inhibition of the Rho/
ROCK/LIMK pathway. Inactivation of LRR1 results in the activa-
tion of cofilin, the remodeling of the actin cytoskeleton, and
increased cell motility in both normal and cancer cells. The
human CRL2LRR1 complex is therefore a central regulator of
actin-based cell movement.
RESULTS
C. elegans LRR-1 is the Substrate-Recognition Subunit
for a CRL2 Complex
In order to identify the proteins that interact with CUL-2, we per-
formed affinity purification of CUL-2-FLAG protein expressed
in C. elegans, followed by mass spectrometry. This analysis
identified the core CRL2 components Rbx1 (RBX-1), Elongin C
(ELC-1), and Elongin B (ELB-1), as well as three SRSs that we
had previously identified: FEM-1, ZYG-11, and ZER-1 (Staros-
tina et al., 2007; Vasudevan et al., 2007). The leucine-rich repeat
protein 1 (LRR-1) also copurified with CUL-2-FLAG (see Supple-
mental Experimental Procedures available online for details). To
test whether LRR-1 functions as an SRS for a C. elegans CRL2
complex, we analyzed two-hybrid interactions between LRR-1754 Developmental Cell 19, 753–764, November 16, 2010 ª2010 Elsand the CRL2 adaptor ELC-1, which binds SRSs to the complex.
LRR-1 interacted with ELC-1 to the same extent as the known
SRS ZYG-11, but neither LRR-1 nor ZYG-11 interacted with an
adaptor for the SCF complex, as expected (Figure 1A). Our
results are in agreement with the finding that the mammalian
ortholog of LRR-1, LRR1, interacts with CUL2 as a putative
SRS, although no function(s) have been reported for this
complex (Kamura et al., 2004).
To explore LRR-1 function, we analyzed the recessive lrr-1
(tm3543) deletion null allele, which is predicted to generate
a truncated LRR-1 protein that lacks 66% of the C-terminal
residues. lrr-1 is an essential gene (Piano et al., 2002), and the
lrr-1(tm3543) allele cannot be maintained as a homozygous
strain. lrr-1(tm3543) heterozygotes appear overtly wild-type,
while homozygous lrr-1 mutant progeny from lrr-1 heterozygote
parents develop to become sterile adults. These animals have
a protruding vulva defect derived from a failure to produce the
full complement of vulva cells (15.0 ± 0.6 [SEM] vulva cells in
lrr-1 mutants versus 22.0 ± 0.0 in lrr-1 heterozygotes or wild-
type animals [n = 10 for each]). In contrast to the deficit of vulval
cells, lrr-1mutants have the normal number of vulval muscle cells
(4.0 ± 0.2 [SD] per lateral side for lrr-1mutants, n = 38, and 4.0 ±
0.0 for both lrr-1 heterozygotes and wild-type, n = 24), and
exhibit a modest increase in the number of epidermal seam cells
(17.6 ± 0.5 [SEM] in lrr-1 mutants versus 16.0 ± 0.0 in wild-type,
n = 20). The few extra seam cells in lrr-1mutants often have less
DNA than normal seam cells, suggesting a cell cycle defect (data
not shown).
The sterility in lrr-1(tm3543) mutants or lrr-1(RNAi) animals is
linked to a striking germline defect that is similar to that of
cul-2 mutants: a reduced number and an enlarged size of germ
cells (Figure 1B). Germ cell DNA content was analyzed to deter-
mine the cell cycle stage of the arrested cells. Wild-type germ
cells demonstrate a bimodal distribution with peaks at 2C and
4C DNA content, corresponding to G1 and G2/M cell cycle
phases, respectively, while lrr-1 and cul-2 mutant germ cells
have only a single peak at 2C (Figure 1C). This indicates that
LRR-1, like CUL-2, is required for the G1-to-S-phase transition
in C. elegans germ cells.
C. elegansCRL2LRR-1 Negatively Regulates CKI-1 Levels
in Germ Cells
Next we attempted to identify the critical substrate for the
CRL2LRR-1 complex. Our previous work pointed to CKI-1 as
the downstream effector for CUL-2 regulated G1-phase
progression in germ cells (Feng et al., 1999). CKI-1 is a CDK-
inhibitor of the Cip/Kip family, which negatively regulates cell
cycle progression in C. elegans (Feng et al., 1999; Hong et al.,
1998). We had previously found that G1-phase arrest in cul-2
mutant germ cells correlates with an accumulation of CKI-1
protein in the distal mitotic region of the gonad (Feng et al.,
1999). We observed a similar accumulation of CKI-1 in the distal
nuclei of lrr-1mutant germ cells (Figure 2A). The CKI-1 signal per
germ cell nucleus was 13 times higher in lrr-1 mutants than in
wild-type (13.1 ± 4.2, n = 71 versus 1.0 ± 0.2, n = 41, arbitrary
units), and similar to the level observed in cul-2 mutants
(11.6 ± 2.0 a.u., n = 29). We observed that GFP::LRR-1 localized
to nuclei in germ cells, which is consistent with a role in
regulating nuclear-localized CKI-1 (Figure 2C).evier Inc.
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A Figure 1. C. elegans LRR-1 Interacts with
the CRL2 Adaptor ELC-1, and lrr-1 Mutants
Share a Germ Cell mutant Phenotype with
cul-2 Mutants
(A) Yeast two-hybrid analysis revealed that LRR-1
binds to the CRL2 adaptor protein ELC-1, similar
to the known CRL2 SRS ZYG-11, whereas neither
LRR-1 nor ZYG-11 binds the SCF adaptor SKR-1.
(B) Gonads dissected from young adult lrr-1
mutant, cul-2 mutant, or wild-type hermaphro-
dites, stained with Hoechst and antinuclear pore
antibody.
(C) Histogram of DNA content in germ cells with 2C
and 4C DNA content labeled on the x axis.
Developmental Cell
CRL2LRR-1 Controls Cell Cycle and Cell MotilityWe previously showed that the G1 phase arrest of cul-2mutant
germ cells is partially suppressed by the deletion of one chromo-
somal copy of the cki-1 gene, suggesting that the arrest results
from the increased levels ofCKI-1 (Fenget al., 1999).Weobserved
a similar effect of reducing CKI-1 levels on the number of germ
cells in lrr-1 deficient animals. While wild-type animals treated
with lrr-1 RNAi had germ cells that were larger and fewer in
number, the germ cells of cki-1(gk132) heterozygotes exposed
to lrr-1 RNAi were similar to those of the wild-type animals (Fig-
ure 2B and legend). This suppression of the germ cell arrest by
removal of one copy of CKI-1 suggests that the accumulation of
CKI-1 mediates the G1 arrest observed in lrr-1 mutants. This
conclusion was supported by the observation that cki-1 feeding-
RNAi treatment can rescue lrr-1mutant germ cells numbers from
76.2 ± 9.4 with no RNAi treatment to 220.8 ± 20.1 with the cki-1
RNAi, n = 10 for each. The cki-1 feeding-RNAi is only modestly
effective at inactivating CKI-1, as determined by a lack of hyper-
plasia in the somatic tissues of wild-type animals. Interestingly,
we observed that more fully inactivating CKI-1 by injecting cki-1Developmental Cell 19, 753–764, NdsRNA into lrr-1 heterozygote parents
produced a genetic enhancement inwhich
lrr-1 mutants had reduced numbers of
postembryonically dividing somatic cells,
including seam cells and vulval cells (data
not shown). CRLs generally have multiple
cellular functions, and this observation
suggests that the complete absence of
CKI-1 is incompatible with the loss of
a distinct CRL2LRR-1 function.
Because CKI-1 accumulates in germ
cells of lrr-1 mutants, we tested whether
CKI-1 is a direct target of the CRL2LRR-1
complex. We observed that CKI-1 protein
had increased turnover when coex-
pressed with the LRR-1 protein in
HEK293T cells, as would be expected
for an E3 substrate (Figure 2D). The level
of CKI-1 was restored by treatment with
the proteasome inhibitor MG132, indi-
cating that the degradation required
the proteasome (Figure 2E). Moreover,
LRR-1 coprecipitated with CKI-1 in
human cells, and the proteins bound
each other in vitro, demonstrating thatthe two proteins physically interact (Figures 2F and 2G). Collec-
tively, our data indicate that C. elegans LRR-1 functions as the
SRS for a CUL-2-based complex that mediates the degradation
of CKI-1 in germ cells to allow progression through G1 phase.
Human CRL2LRR1 Targets p21Cip1 for Ubiquitylation
and Degradation
In mammals, there are three Cip/Kip family paralogs, p21Cip1,
p27Kip1, and p57Kip2, that inhibit multiple CDK-cyclin complexes
(Sherr and Roberts, 1999). To determine whether LRR1 nega-
tively regulates CDK-inhibitors in human cells, we analyzed the
levels of the three Cip/Kip CKIs upon LRR1 knockdown in
HeLa cells. The level of p21 increased significantly upon LRR1
knockdown, but there was no measurable effect on p27 or p57
protein levels (Figure 3A). CUL2 knockdown also increased
p21 levels to an extent comparable with that of LRR1 knockdown
(Figure 3A). While our initial experiments employed pools of
LRR1 siRNAs, individual LRR1 siRNAs also produced an accu-
mulation of p21 (Figure 3B). The LRR1 siRNAs effectivelyovember 16, 2010 ª2010 Elsevier Inc. 755
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Figure 2. C. elegans LRR-1 Negatively
Regulates CKI-1 Levels in Germ Cells and
Stimulates the Proteasome-Mediated
Degradation of CKI-1 when Expressed in
Human Cells
(A) Gonads dissected from young adult lrr-1
mutant, cul-2 mutant, or wild-type hermaphro-
dites, stained with anti-CKI-1 and anti-nuclear
pore antibodies.
(B) Genetic interaction between lrr-1 and cki-1.
Differential-interference contrast (DIC) images of
thedistal gonadofwild-typeorcki-1/+ youngadults
treated with lrr-1 RNAi, and cki-1/+ young adults
with no RNAi treatment (the latter is indistinguish-
able from that of wild-type). The distal end of the
gonad is to the left. In this experiment (out of three
experiments with similar results), 16/16 (100%) of
lrr-1(RNAi); cki-1/+ animals examined had germ
cells of normal size, while 16/16 lrr-1(RNAi) animals
had fewer, enlarged germ cells, and 7/7 cki-1/+
animals had germ cells of normal size.
(C) Fluorescence and DIC micrographs of the
distal tip of a dissected gonad from an adult that
expresses GFP::LRR-1 translational fusion under
the control of the germline-specific pie-1 pro-
moter. Scale bars in (A)–(C) are 10 mm.
(D) Pulse-chase experiment showing increased
turnover of CKI-1 protein in the presence of
LRR-1. VSVG-CKI-1 was expressed in HEK293T
cells, in the presence or absence of FLAG-
LRR-1, and in the presence of MG132 proteasome
inhibitor. At time 0, MG132 was removed and
protein synthesis was blocked by cycloheximide
(CHX). Cells were harvested at the indicated time
points and analyzed by western blot with the
indicated antibodies.
(E) Proteasome inactivation blocks the LRR-1-
mediated destabilization of CKI-1. VSVG-CKI-1
and FLAG-LRR-1 were coexpressed in HEK293T
cells in the presence or absence of MG132, and
cell lysates were analyzed by western blotting
with the indicated antibodies. A cross-reacting
band served as a loading control.
(F) HSV-LRR-1 coprecipitates with FLAG-CKI-1 when coexpressed in HEK293T cells. Immunoprecipitated proteins were eluted from the beads with 0.4 mg/ml
FLAG peptide and then analyzed by western blot with the indicated antibodies.
(G) LRR-1 andCKI-1 bind each other in vitro. 35S-labeled in vitro translated LRR-1 or CKI-1 proteins were incubated with GST, GST-CKI-1, or GST-LRR-1 purified
on glutathione Sepharose beads, and the beadswere washed and analyzed by SDS-PAGE/autoradiography. Input is 10%of the in vitro translated protein used in
the binding reactions. The two right panels are Coomassie-stained gels showing the relative amounts of GST and GST-fusion proteins used in the reactions.
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CRL2LRR-1 Controls Cell Cycle and Cell Motilityknocked down the expression of exogenous 3xFLAG-LRR1
while producing an accumulation of endogenous p21 (Figure 3C).
Expression of an LRR1 rescue construct that is resistant to LRR1
siRNA prevented the increase in endogenous p21 level upon
LRR1 siRNA treatment (Figure 3D). The half-life of endogenous
p21 protein was markedly extended in LRR1 or CUL2 knock-
down cells, indicating that LRR1 and CUL2 increase the post-
translational turnover of p21 (Figures 3E and 3F).
We sought to determine if the CRL2LRR1 complex directly
targets p21 for degradation by testing for physical interaction
between p21 and LRR1. We found that exogenous p21 and
FLAG-LRR1 reciprocally coimmunoprecipitated each other in
HEK293T cells (Figure 4A). Additionally, both untagged p21
and Myc-tagged p21 were able to reciprocally bind endogenous
CUL2 in HEK293T cells, providing further evidence that p21
binds to the CRL2LRR-1 complex (Figure 4B; data not shown).756 Developmental Cell 19, 753–764, November 16, 2010 ª2010 ElsAs a final test of whether p21 is a CRL2LRR1 substrate, we
determined if CRL2LRR1 ubiquitylates p21. Expression of
FLAG-LRR1 in HeLa cells significantly enhanced the in vivo ubiq-
uitylation of endogenous p21, while a FLAG-LRR1D mutant
protein that lacks the VHL-box so that it cannot bind to the
CRL2 complex did not stimulate p21 ubiquitylation (Figure 4C).
The CRL2LRR1 complex was also able to ubiquitylate p21
in vitro (Figure 4D). Overall, our data indicate that the human
CRL2LRR1 complex directly ubiquitylates p21 to target it for
proteasome-mediated degradation.
HumanCRL2LRR1 Regulates p21 Levels in theCytoplasm
Unlike C. elegans germ cells that undergo G1 phase arrest upon
inactivation of LRR-1 or CUL-2, we did not observe an obvious
effect on the proliferation of human cells from the knockdowns
of LRR1 or CUL2, despite the significantly elevated p21 levels.evier Inc.
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Figure 3. Endogenous p21 Is Negatively Regulated by
LRR1 and CUL2 in Human Cells
(A) HeLa cells were transfected with siRNA for GFP (control),
LRR1, or CUL2, and the levels of the indicated proteins in
whole cell lysates were assessed by western blot.
(B) The efficiency of individual LRR1 siRNAs (#1–#4) in
increasing p21 levels is compared with a pool of all four
individual LRR1 siRNAs (pool).
(C) HeLa cells stably expressing 3xFLAG-LRR1 were trans-
fected with pooled LRR1 siRNAs or LRR1 siRNA #2, and
the levels of 3xFLAG-LRR1 were detected with anti-FLAG
antibody.
(D) Expression of an siRNA-resistant LRR1 rescue construct
prevents the increase of p21 levels in cells treated with LRR1
siRNA. HeLa cells were cotransfected with LRR1 siRNA #1
or GFP siRNA, and with an expression construct encoding
either FLAG-tagged wild-type LRR1 or a silent mutant LRR1
with five mismatches in the region targeted by the siRNA.
(E) p21 protein turnover in LRR1 or CUL2 knockdown cells.
HeLa cells were transfected with the indicated siRNAs in the
presence of MG132. At time 0, MG132 was removed, and
further protein synthesis was blocked by cycloheximide
(CHX). Cells were collected at the indicated time points and
analyzed by western blot.
(F) Graph of p21 levels (standardized relative to the loading
control) for the turnover rate experiment in (E). The values for
each siRNA treatment were set at 100% for the time 0 values.
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CRL2LRR-1 Controls Cell Cycle and Cell MotilityThe cell cycle distribution of LRR1 knockdown HeLa cells was
not appreciably different from control cells, while CUL2 knock-
down cells had only a small increase in the percentage of G1
phase cells (Figure 5A). Thus, the CRL2LRR1 complex does not
appear to significantly affect cell cycle progression.
CDK-cyclin activity and cell cycle progression is regulated by
p21 that is nuclear localized (Abukhdeir and Park, 2008). In
contrast, p21 localized to the cytoplasm has functions that are
independent of cell cycle regulation (Besson et al., 2008). To
distinguish which subcellular pool of p21 was affected by loss
of the CRL2LRR1 complex, we analyzed nuclear and cytoplasmic
fractions of HeLa cells. Nuclear p21 levels were not significantly
increased upon LRR1 or CUL2 knockdown; however, the level of
cytoplasmic p21 was markedly elevated (Figure 5B). This eleva-
tion does not require the PIP-box motif of p21, which is required
for PCNA-dependent CRL4Cdt2-mediated degradation of
nuclear p21 (Abbas et al., 2008; Kim et al., 2008; Nishitani
et al., 2008) (Figure S1 available online). Consistent with its role
in regulating cytoplasmic p21, FLAG-LRR1 localizes to the
cytoplasm in HeLa cells and is largely excluded from the nucleus
(Figure 5C). CUL2 is also predominantly cytoplasmic (Figure 5B).
Human CRL2LRR1 Degrades p21 to Control Actin
Cytoskeleton Remodeling
Cytoplasmic p21 has been shown to bind and inhibit ROCK1 and
thereby block the RhoA/ROCK/LIMK pathway from inhibiting
cofilin via phosphorylation (Lee and Helfman, 2004). To deter-
mine if LRR1 inactivation produces a similar effect on the RhoADevelopmental Cell 19, 7pathway, we asked whether an LRR1 knockdown
affected the level of cofilin phosphorylation on
Ser3, the target site of LIM kinase. Indeed, phos-
pho(Ser3)-cofilin levels (but not total cofilin proteinlevels) decreased significantly in LRR1 knockdown HeLa cells
(Figure 5D). Similar results were obtained upon LRR1 knock-
down in the glioblastoma tumor cell line T98-G (data not shown).
TheRhoA/ROCK/LIMKpathway protects stress fibers from the
depolymerizing activity of cofilin. When the pathway is inacti-
vated, cofilin can induce the disassembly of F-actin in stress
fibers. The released G-actin is used at the cell periphery for new
filament formation via Rac/Arp2/3-dependent processes to
form membrane protrusions (Kedrin et al., 2007; Pollard and
Borisy, 2003; Ridley et al., 2003). Thus, we sought to determine
if stress fibers are affected by LRR1 knockdown. We observed
that LRR1 knockdown cells indeed had a marked decrease in
the abundance of stress fibers, with a concomitant increase in
F-actin staining at the cell periphery when compared with control
cells (Figure 6). The expression of an LRR1-silent mutant
construct that is resistant to LRR1 siRNA suppressed the loss of
stress fibers in HeLa cells treated with LRR1 siRNA, thereby con-
firming the specificity of the siRNA effect (Table S1; Figure 3D).
We noticed that HeLa cells treated with LRR1 siRNA did not
contact each other as closely as control cells, being situated
an appreciable distance from each other, while control cells
were tightly associated in clusters (Figure 6A). CUL2 knockdown
HeLa cells had a similar cytoskeleton appearance and lack of
cell-cell contacts (data not shown). Similar actin cytoskeleton
rearrangements were also observed in T98-G glioblastoma fibro-
blasts treated with LRR1 or CUL2 siRNA (data not shown). The
separation of cells suggests an increased motility after cell divi-
sion, analogous to the scattering effect (Grotegut et al., 2006).53–764, November 16, 2010 ª2010 Elsevier Inc. 757
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Figure 4. LRR1 Physically Associates with p21 and Stimulates Its
Ubiquitylation
(A) p21 physically interacts with LRR1. p21 and FLAG-LRR1 were coex-
pressed in HEK293T cells as noted by (+) symbols above the lanes. Anti-p21
or anti-FLAG immunoprecipitations (IP) and lysates were analyzed by western
blot with the indicated antibodies.
(B) p21 interacts with endogenous CUL2. Myc-p21 was expressed in
HEK293T cells, and anti-Myc or anti-CUL2 immunoprecipitations were
analyzed by probing with the indicated antibodies.
(C) Overexpression of LRR1 stimulates the in vivo ubiquitylation of endoge-
nous p21 in HeLa cells. FLAG-LRR1 or FLAG-LRR1D (with deletion of the
VHL-box motif that is required for binding Elongin C) was expressed in HeLa
cells with HA-ubiquitin (noted above the lanes) in the presence of MG132.
Endogenous p21 was immunoprecipitated under denaturing conditions, and
analyzed by western blot with the indicated antibodies.
(D) In vitro ubiquitylation of p21 by the CRL2LRR1 complex. FLAG-LRR1 and
p21 were expressed in HEK293T cells (noted at the top), in the presence of
MG132. The CRL2LRR1 complex was immunoprecipitated with anti-FLAG
antibody (first IP), which coimmunoprecipitated p21. The CRL2LRR1 complex,
with bound p21, was subjected to an in vitro ubiquitylation reaction. p21 was
subsequently reimmunoprecipitated under denaturing conditions, followed by
immunoblot with antibodies to detect HA-ubiquitin and p21. Asterisks mark
nonspecific bands.
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CRL2LRR-1 Controls Cell Cycle and Cell MotilityIn addition to the cytoskeleton rearrangements, we observed
morphological changes upon LRR1 knockdown in HeLa cells:
19.4% (n = 290 cells) possessed an abnormally elongated form
with a length-to-width ratio at least three times greater than
that of control cells; no such elongated cells were observed in
the control culture (n = 450 cells) (Figure 6A). Similar observa-
tions were made in multiple experiments. Cell elongation is a
known phenotype associated with inhibiting the RhoA pathway,758 Developmental Cell 19, 753–764, November 16, 2010 ª2010 Elsarising as a consequence of actin cytoskeleton rearrangement
(Arthur and Burridge, 2001).
Importantly, a double knockdown of LRR1 and p21 sup-
pressed the LRR1 knockdown phenotypes. Stress fiber
abundance was restored in the cells treated with LRR1 siRNA
plus p21 siRNA, to an extent comparable with control cells
(Figure 6B; Table S2). p21 siRNA alone did not affect the
abundance of stress fibers relative to control cells (Figure 6B;
Table S2). Cell populations with a double knockdown of LRR1
and p21 lacked elongated cells, and cells were predominantly
in colonies with close cell contact. Thus, our data supports the
model that CRL2LRR1 acts to maintain the integrity of actin stress
fibers and cell morphology of stationary cells by regulating p21
levels.
Our initial experiments with LRR1 siRNA used cancer cell lines.
To determine if CRL2LRR1 has a similar role in regulating the actin
cytoskeleton in normal human cells, we analyzed IMR-90 normal
human fetal lung fibroblasts. IMR-90 cells showed a similar
elevation of p21 levels upon treatment with LRR1 siRNA or
CUL2 siRNA (Figure 6C; data not shown). LRR1 knockdown
IMR-90 cells continued to actively divide and did not have major
deviations from the normal cell cycle distribution (Figure S2).
LRR1 knockdown also decreased stress fiber abundance and
increased the level of peripheral F-actin in IMR-90 cells. Signifi-
cantly, the LRR1 knockdown IMR-90 cells had prominent
filopodia-like actin-rich membrane protrusions that were rare in
control cells (Figure 6C). Cells of such atypical morphology
comprised a significant proportion of the LRR1 knockdown cell
population: 64.9% (n = 111) versus 7.1% (n = 113) in the control
population. Therefore, CRL2LRR1 regulates the actin cytoskel-
eton in both normal and cancer cells.
Human CRL2LRR1 Regulates Cell Motility
While the inhibition of the RhoA pathway is associated with
increased cell motility (Ridley et al., 2003), there are no published
reports on whether the accumulation of cytoplasmic p21 acti-
vates cell motility. We sought to determine if the LRR1 knock-
down (with its concomitant higher level of cytoplasmic p21)
increases cell motility. Using a transwell assay, in which cells
migrated through a membrane in response to a serum gradient,
we observed a greater than 3-fold increase in the number of
LRR1 knockdown HeLa cells that migrated across the mem-
brane compared with control cells (Figure 7C). LRR1 siRNA
knockdown of IMR-90 cells also produced a 2-to-3-fold increase
in motility in the transwell assay (Figure 7D).
In a wound-healing assay, LRR1 knockdown IMR-90 cells
(treated with mitomycin C to block proliferation) demonstrated
noticeably faster migration into a circular cleared area as early
as 24 hr post-wounding, and, at 72 hr, the LRR1 knockdown cells
had filled in most of the previously empty area, while the area
in the control cell culture was still largely empty (Figure 7A).
Analogous results were obtained with HeLa cells in the wound-
healing assay with either a circular cleared area or scratches
(Figure 7B; data not shown). LRR1 inactivation therefore stimu-
lates the motility of both normal and cancer cells. Importantly,
the increased motility of LRR1 knockdown cells was dependent
on p21, as the double knockdown of LRR1 and p21 suppressed
the cell motility associated with LRR1 knockdown in both the
transwell and wound-healing assays (Figure S3).evier Inc.
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Figure 5. CRL2LRR1 Targets the Degradation of Cytoplasmic p21, Which Is Associated with Changes in the Phosphorylation of Cofilin
(A) Flow cytometry profiles of DNA content of HeLa cells transfected with siLRR1, siCUL2, or siGFP. Cell cycle phase distributions were determined using the
ModFit program.
(B) Subcellular fractionation of HeLa cells transfected with LRR1 or CUL2 siRNA. Total (T), cytoplasmic (C), or nuclear (N) fractions of cell lysates were analyzed by
western blot with the indicated antibodies. A longer exposure of the anti-p21 blot (second panel from the top) is presented to show the p21 levels in control cells.
Immunoblots of anti-a-tubulin (a cytoplasmic marker) and anti-PARP-1 (a nuclear marker) demonstrate the purity of the fractionation.
(C) Cytoplasmic localization of LRR1. HeLa cells were transiently transfected with FLAG-LRR1 and examined by immunofluorescence with anti-FLAG antibody.
DNA was stained with Hoechst.
(D) Ser3-phosphorylation of cofilin is reduced in LRR1 knockdown cells. HeLa cells were transfected with LRR1 siRNAs (pooled or individual siRNAs) or with GFP
siRNA, and whole cell lysates were analyzed by immunoblot for p21, cofilin, and phospho-cofilin (Ser3). See also Figure S1.
Developmental Cell
CRL2LRR-1 Controls Cell Cycle and Cell MotilityAnalysis of Cell Migration in C. elegans lrr-1 Mutants
Given the role that human LRR1 has in regulating cell motility, we
asked whether cell migration was altered in C. elegans somatic
cells. We analyzed the migration of three cell types: distal tip
cell (DTC), sex myoblast, and touch receptor neurons. The DTC
migration pattern was normal in 93% (28/30) of lrr-1 mutants,
while in 2/30 lrr-1 mutants, the two DTCs migrated on the same
lateral side of the animal (rather than on different lateral sides
as in the wild-type). A similar defect was observed in 1/30 lrr-1
(RNAi) animals. This defect of the gonad on the same lateral
side is not observed in other DTCmigrationmutants (Hedgecock
et al., 1987; Nishiwaki, 1999), and may reflect a defect in the
shape of the initial gonad primordium rather than a migration
defect. In 95% (36/38) of lrr-1 mutants, the vulva muscles were
positioned normally, indicating that the precursor cell, the sex
myoblast, hadmigratedproperly. In the twocasesofmisposition-
ing, the vulvamuscle cellswere localizedboth anterior andposte-
rior to the vulva, implying that the sex myoblasts had initiallyDevelopmemigrated properly to the mid-gonad region. Finally, we analyzed
the positions of five of the six touch receptor neurons (TRNs),
which undergomigration and axon projections during the embry-
onic and larval stages. In 10/10 lrr-1mutants, the TRNs and their
axons were normally positioned (Figure S4). Further, it is unlikely
that there are extensive defects in neuron and axon migrations in
lrr-1 mutants, as such defects produce an uncoordinated (Unc)
phenotype (Hedgecock et al., 1987), while lrr-1 mutants have
normal locomotion (data not shown). We therefore conclude
that LRR-1 is not required for proper cell migration in C. elegans.
DISCUSSION
C. elegans CRL2LRR-1 Targets the Degradation
of the CDK-Inhibitor CKI-1 in Germ Cells
to Allow G1 Phase Progression
We identified LRR-1 as a protein that physically associates with
CUL-2 in C. elegans. LRR-1 binds to the adaptor protein forntal Cell 19, 753–764, November 16, 2010 ª2010 Elsevier Inc. 759
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Figure 6. LRR1 Knockdown Is Associated with Remodeling of the Actin Cytoskeleton in HeLa Cells and in IMR-90 Normal Human Fetal Lung
Fibroblasts
(A) HeLa cells transfected with LRR1 siRNA were stained with rhodamine-phalloidin to visualize the actin cytoskeleton, and with Hoechst to visualize DNA.
The lower panel presents an elongated cell in the LRR1 knockdown cell population.
(B) The loss of stress fibers in LRR1 knockdown HeLa cells is suppressed by coknockdown of p21. A western blot (bottom right) demonstrates the levels of p21 in
the knockdown cell populations.
(C) IMR-90 cells transfected with LRR1 or GFP siRNAwere stained as in (A). Western blot analysis of the cell lysate (presented below) demonstrates elevated p21
in siLRR1 treated IMR-90 cells. See also Figure S2 and Tables S1 and S2.
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CRL2LRR-1 Controls Cell Cycle and Cell MotilityCRL2 complexes, as expected for an SRS (Bosu and Kipreos,
2008). Both lrr-1 and cul-2 mutants share the phenotype of
G1-phase cell cycle arrest in germ cells. Further, our data
suggest that the accumulation of the CDK-inhibitor CKI-1 in
lrr-1 and cul-2 mutants causes the G1 arrest, as the phenotype
is suppressed by lowering the cki-1 gene copy number.
CKI-1 appears to be a direct substrate of the CRL2LRR-1
complex. The coexpression of LRR-1 and CKI-1 in human cells
leads to the proteasome-mediated degradation of CKI-1,
presumably via the incorporation of C. elegans LRR-1 into
a CRL2 complex with core human CRL2 components (Starostina
et al., 2007). Collectively, our data indicate that LRR-1 functions
as the SRS for a CRL2LRR-1 ubiquitin ligase complex that targets
CKI-1 for degradation to ensure G1-to-S-phase progression in
C. elegans germ cells.
Human CRL2LRR1 Targets the CDK-Inhibitor p21Cip1
for Degradation to Regulate the Actin Cytoskeleton
In this work, we show that the human CRL2LRR1 complex has the
conserved function of targeting a Cip/Kip CDK-inhibitor for
degradation. Human LRR1 regulates the abundance of the CKI
p21Cip1, but does not affect the levels of the related CKIs
p27Kip1 and p57Kip2. CUL2 and LRR1 physically interact with760 Developmental Cell 19, 753–764, November 16, 2010 ª2010 Elsp21, and the overexpression of LRR1 stimulates the in vivo
ubiquitylation of p21. Additionally, the CRL2LRR1 complex
ubiquitylates p21 in vitro. Thus, our data indicate that p21 is a
direct substrate for human CRL2LRR1. However, the CRL2LRR1-
mediated degradation of the CDK-inhibitor p21 does not appear
to regulate the cell cycle.
Cytoplasmic p21 has been shown to have important cellular
roles that are independent of cell-cycle regulation: it can act as
an anti-apoptotic factor or as a regulator of the actin cytoskel-
eton. These alternative functions appear to underlie its role as
an oncoprotein (Besson et al., 2008; Blagosklonny, 2002).
Elevated levels of cytoplasmic p21 are associated with highly
aggressive cancers (Abukhdeir and Park, 2008). Significantly,
high cytoplasmic p21 levels are observed in cancers that are
induced by the Ras andHER2/neu oncogenes (Lee andHelfman,
2004; Xia et al., 2004). The accumulation of cytoplasmic p21 has
been linked to the loss of stress fibers in Ras-transformed cells
(Lee and Helfman, 2004). Elevated cytoplasmic p21 levels have
been attributed in part to transcriptional stimulation (e.g., via
Ras or p53) (Heliez et al., 2003; Lee and Helfman, 2004), and
have been linked to Akt/PKB- or PKC-mediated phosphorylation
of p21 (Child and Mann, 2006; Rodriguez-Vilarrupla et al., 2005;
Zhou et al., 2001). How cytoplasmic p21 protein stability isevier Inc.
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Figure 7. LRR1 Knockdown Increases Cell
Motility
(A) Wound-healing assay (Oris cell migration
assay). IMR-90 cells were transfected with LRR1
or GFP siRNA and were placed into wells con-
taining disks in the center for the creation of a
migration detection zone. After cells reached con-
fluency, they were treated with mitomycin C to
prevent cell division, and the disks were removed
to allow cells to migrate to the center of the well.
The edge of the cleared area at 24 hr post-disk
removal is shown at 253 magnification, and the
center of the cleared area is shown at 48 hr and
72 hr post-disk removal (503 magnification, DIC).
(B) Wound-healing cell migration assay with LRR1
knockdown HeLa cells. Confluent HeLa control or
LRR1 knockdown cells were treated with mito-
mycin C and cells were scraped to form a
0.8 mm-wide lane lacking cells. The images are
24 hr post-wound healing. White dotted lines indi-
cate the borders of the wound.
(C) LRR1 knockdown cells have increased motility
in a transwell assay. The graph presents the
number of GFP siRNA or LRR1 siRNA treated
HeLa cells that migrated across the transwell
membrane in seven random field-of-views. Error
bars are SD. Panels on the right are representative
images of cells that migrated across the transwell
membrane (phase contrast, 2003 magnification).
Cells are indicated by black arrows; the filter pores
are indicated by white arrows.
(D) Graph of the transwell cell-migration assay of
IMR-90 cells, performed as described in (C).
(E) Flow chart reflecting the functions of CRL2LRR1
uncovered in this study. See text for details.
See also Figures S3 and S4.
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CRL2LRR-1 Controls Cell Cycle and Cell Motilitycontrolled has not previously been studied, although it has been
implicated to have an important role. In Ras-transformed mouse
fibroblasts, the accumulation of cytoplasmic p21 requires Ras/
Raf/MEK activity (to induce p21 transcription) and Ras/PI3K/
AKT activity (to promote p21 cytoplasmic retention), but the
inhibition of either pathway does not produce a decline in p21
levels if the proteasome is inhibited, suggesting a critical role
for proteolysis (Lee and Helfman, 2004).
We present evidence for a ubiquitin ligase that specifically
regulates the level of cytoplasmic p21. CRL2LRR1 is likely to
target p21 only in the cytoplasm, because both LRR1 and
CUL2 proteins are predominantly cytoplasmically localized in
HeLa cells. Cytoplasmic p21 regulates the actin cytoskeleton
by binding and inhibiting the Rho-associated kinase ROCK.
ROCK functions in the Rho/ROCK/LIMK pathway to activate
LIM kinase, which phosphorylates cofilin on its serine 3 residue
in order to inhibit cofilin. When ROCK is inhibited, the actin-Developmental Cell 19, 753–764, Ndepolymerization function of cofilin is
activated and the subsequent disas-
sembly of actin filaments facilitates actin
cytoskeleton remodeling (Besson et al.,
2008; Lee and Helfman, 2004; Tanaka
et al., 2002). In this study, we demon-
strate that LRR1 inactivation causes adramatic reduction in the inhibitory phosphorylation of cofilin
(Figure 7E).
The major cellular processes driven by cytoskeleton remodel-
ing are morphogenesis and cell motility. The inhibition of the
Rho/ROCK pathway results in loss of stress fibers, and is often
associated with cell elongation (including axon extension in
neurons) and increased cell motility (Fournier et al., 2003; Kedrin
et al., 2007; Ridley et al., 2003). Elevated cytoplasmic p21 has
been shown to produce a loss of stress fibers in NIH 3T3 fibro-
blasts and to promote neurite extension in neuroblastoma cells
and hippocampal neurons (Lee and Helfman, 2004; Tanaka
et al., 2002). However, direct experiments showing the effect
of cytoplasmic p21 on cell motility have not been reported.
Here we demonstrate that in both cancer and normal human
cells, the accumulation of cytoplasmic p21 (upon LRR1 inactiva-
tion) facilitates cytoskeleton rearrangement, including loss of
stress fibers, enrichment of actin filaments at the cell periphery,ovember 16, 2010 ª2010 Elsevier Inc. 761
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CRL2LRR-1 Controls Cell Cycle and Cell Motilitythe formation of membrane protrusions, changes in cell
morphology, and increased cell motility.
The contrast between the conservation of the CRL2LRR-1
substrate and divergence in cellular roles for CRL2LRR-1 between
C. elegans germ cells and human cells is striking. This difference
in function is linked to targeting different subcellular pools of the
CDK inhibitor.C. elegans LRR-1 is nuclear localized in germ cells
and regulates the abundance of nuclear CKI-1 to control the cell
cycle, while human LRR1 is cytoplasmic localized and regulates
the abundance of cytoplasmic p21 to control the actin cytoskel-
eton and cell motility. The cell migration events that we assessed
appear to largely occur normally inC. elegans lrr-1mutants, sug-
gesting that LRR-1 does not regulate cell motility in nematodes.
An interesting question is how the degradation of CDK inhibitors
by the same E3 complex evolved to regulate such divergent
functions. A corollary to this is the question of when the regula-
tion of the cytoskeleton by Cip/Kip CKIs evolved. Currently,
Cip/Kip CKIs have only been linked to the regulation of the actin
cytoskeleton in mammals. It is possible that the ability of CKIs to
regulate the actin cytoskeleton occurred later in evolution and,
when this new function arose, an already-existing means of
regulating the CKI (via CRL2LRR-1-mediated degradation) was
employed to regulate this new function.
Human LRR1 is expressed in most tissues (Jang et al., 2001),
and therefore LRR1-mediated regulation of the cytoskeleton and
cell motility may occur in a broad range of cell types. Elevated
levels of cytoplasmic p21 are correlated with a number of
developmental events: the differentiation of monocytes and
neurons, neurite extension and axonal regeneration, and the
conversion of pancreatic myofibroblasts to fibroblasts during
pancreatic fibrosis (Asada et al., 1999; Manapov et al., 2005;
Tanaka et al., 2002, 2004). In nonmotile cells, our work suggests
that LRR1 prevents the inhibition of the Rho/ROCK/LIMK
pathway by maintaining low levels of cytoplasmic p21. In cancer
cells, elevated cytoplasmic p21 levels are associated with poor
cancer prognosis (McBride et al., 2002; Winters et al., 2001;
Xia et al., 2004). The inactivation of the CRL2LRR1 pathway may
contribute to the accumulated cytoplasmic p21 levels in tumors,
thereby increasing cell motility and metastasis, particularly for
those cancer cells that utilize a mesenchymal type of migration
(Sanz-Moreno et al., 2008; Wolf et al., 2003). Our work intro-
duces the possibility that CRL2LRR1 functions as a safeguard to
prevent metastasis. In this light, it is interesting that the human
chromosomal region containing the LRR1 gene, 14q21.3, is
preferentially lost in metastatic cancer relative to nonmetastatic
cancer for lung adenocarcinoma, colorectal carcinoma, and
breast cancer (Goeze et al., 2002; Knosel et al., 2004; Richard
et al., 2000), and its loss is associated with poor prognosis for
squamous cell carcinomas of the head and neck (Pehlivan
et al., 2008). Defining how the CRL2LRR1-mediated degradation
of p21 is regulated is an important future goal, with implications
for both cancer and development.EXPERIMENTAL PROCEDURES
C. elegans Analysis
RNAi experiments were performed by the feeding RNAi method, as described
(Timmons et al., 2001), using full-length lrr-1 or cki-1 cDNAs (from the start
codon to the stop codon) cloned between double T7 promoters in the vector762 Developmental Cell 19, 753–764, November 16, 2010 ª2010 ElspPD129.36. The dsRNA was expressed in E. coli strain HT115. For lrr-1
RNAi, young adults were placed on plates containing dsRNA-expressing
HT115, and then transferred to fresh RNAi plates at 12 hr (second plate) and
24 hr (third plate). The progeny from the second plate were examined by
DIC microscopy. For cki-1 RNAi, L2-stage larvae were placed on dsRNA-ex-
pressing HT115, and the numbers of germ cells were analyzed in young adult
progeny by counting Hoechst-stained germ cell nuclei with epifluorescence.
Young adults were frozen, fixed in acetone for 2 min, and stained with 1 mg/ml
Hoechst 33258. The DNA content of Hoechst 33258-stained germ cells in
dissected gonads was determined as described (Kim et al., 2008) and inter-
nally standardized to the 2C signal from the somatic gonadal distal tip cell
(DTC).
Affinity purification of CUL-2::FLAG-associated proteins was performed as
previously described (Starostina et al., 2007). Anti-CKI-1 immunofluorescence
of dissected gonads was as described (Feng et al., 1999). Please see Supple-
mental Experimental Procedures for more details.
siRNA and Cell Cycle Analysis
HeLa cells were transfected with 100 nM of siRNAs (for the pooled LRR1
siRNA, each siRNA was at 25 nM) using Oligofectamine (Invitrogen) or X-trem-
eGENE transfection reagent (Roche). T98-G cells were transfected with
100nM of siLRR1#1 and siCUL2 using X-tremeGENE.
IMR-90 cells (used at 3–4 passages after receiving from ATCC) were trans-
fected by siLRR1#1 or siCUL2 at 50 nM using jetPRIME transfection reagent
(Polypus Transfection Inc.).
X-tremeGENE transfection reagent was used for the cotransfection of siRNA
and DNA. The transfection reagents were used in accordance with the manu-
facturers’ instructions. Transfections were performed two or three times
sequentially. Cells were collected 60–72 hr after the first transfection and
analyzed by western blot, microscopy, or cell migration assay.
DNA content was determined in siRNA-transfected HeLa cells using flow
cytometry. Cells were fixed with 70% ethanol, treated with 20 mg/ml RNase
(Sigma), and stained with 0.5 mg/ml propidium iodide (Sigma) followed by
analysis with a FACSCalibur flow cytometer (Beckton-Dickinson). ModFit
software (Verity) was used to determine cell cycle-phase distributions.
Immunofluorescence and Immunoprecipitation
Immunoprecipitation of proteins ectopically expressed in HEK293T or HeLa
cells was performed as described (Kim et al., 2008; Starostina et al., 2007).
For immunofluorescence, HeLa, T98G, and IMR-90 cells were fixed in 4.0%
paraformaldehyde in PBS for 10 min at room temperature, permeabilized
with 0.4% Triton X-100 in PBS, and stained with anti-FLAG M2 antibodies
(1:600) followed by incubation with Alexa-Fluor 488 secondary antibodies,
and/or with Rhodamine-phalloidin (1:500), and with Hoechst dye.
Pulse-Chase and Cell Fractionation Experiments
For pulse-chase experiments, 18–20 hr after transfection, cell cultures were
supplemented with 10 mM of the proteasome inhibitor MG132 (Calbiochem);
6 hr later, MG132 was removed and 25 mg/ml cycloheximide (Sigma) was
added (time 0 in the assay). Cells were lysed by boiling with 1.5% SDS, and
analyzed by western blot. Cell fractionation was performed as in Sarcinella
et al. (2007). See Supplemental Experimental Procedures for details.
Ubiquitylation Assays
For in vivo ubiquitylation, FLAG-LRR1 or FLAG-LRR1D (VHL box deletion) was
coexpressed with HA-ubiquitin in HeLa cells. 14 hr after transfection, cells in a
6-well plate were subcultured into a 60 mm plate. 24 hr later, the cultures were
supplemented with 10 mM MG132, and 5 hr later, cells were lysed by boiling
with 1% SDS and diluted 10 times with the binding buffer: 50 mM Tris-HCl
(pH 7.6); 150 mM NaCl; 0.1% NP-40; 2 mM DTT; 1 mM EDTA; protease inhib-
itor cocktail (Roche); phosphatase inhibitor cocktail (Roche); 15 mM MG132;
and 5 mM iodoacetamide (Sigma). Endogenous p21 was precipitated with
anti-p21 antibodies, and analyzed by western blot for p21 and for HA-ubiquitin
covalently bound to p21.
For in vitro ubiquitylation, FLAG-LRR1 and p21 were coexpressed in
HEK293T cells for 26 hr, and for the last 6 hr, in the presence of 10 mM
MG132. Cells were lysed with NP-40 buffer: 0.5% NP-40; 50 mM Tris-HCl
(pH 7.6); 150 mM NaCl; 10% glycerol; protease inhibitor cocktail; 2 mMevier Inc.
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CRL2LRR-1 Controls Cell Cycle and Cell MotilityDTT; and 15 mM MG132; supplemented with 100 U/ml OmniCleave endonu-
clease (Epicentre Biotechnologies) and 10 mM MgCl2. FLAG-LRR1 was
precipitated with anti-FLAG antibody in the presence of 1 mM EDTA,
2.5mM iodoacetamide, and 2.5mMo-phenanthroline. The precipitated immu-
nocomplex was incubated with 30 ml of ubiquitylation reaction mix containing
50mMTris-HCl (pH 7.4), 5 mMMgCl2, 2 mMNaF, 10 nM okadaic acid, 0.6 mM
DTT, 2 mM ATP, 0.6 ml of energy generation solution (Biomol Int., LP), 1 mg
HA-ubiquitin (Boston Biochem), 100 ng E1 (Biomol Int., LP), 400 ng E2-Ub-
cH5a (Biomol Int., LP), 2 mM ubiquitin aldehyde (Biomol Int., LP), and 15 mM
MG132. Reactions were incubated at 30C for 90 min and terminated by
boiling with 1% SDS. p21 was immunoprecipitated in a buffer containing
0.1% SDS and 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 0.1% NP-40, 2 mM
DTT, 1 mM EDTA, protease inhibitor cocktail, phosphatase inhibitor cocktail,
15 mM MG132, and 5 mM iodoacetamide (Sigma), and analyzed by western
blot for HA-ubiquitin and for p21.
Cell Migration Assays
For the transwell assay, 5x104 cells suspended in DMEM with 0.1% FBS were
placed onto a Transwell filter with 8.0 mm pores (BD Biosciences), and allowed
tomigrate toward 10%FBS in DMEM for 8 hr at 37C in 5%CO2. The filter was
then fixed with 4% formaldehyde in PBS for 20 min at room temperature and
stained with Trypan blue or Coomassie Blue. After removing nonmigrated cells
on the inner side of the filter with a cotton swab, cells that had migrated across
the membrane to the outer side of the filter were counted at 100x magnifica-
tion, and representative fields-of-view images were captured at 200x magnifi-
cation. Cell counts for seven to ten random fields of view for each condition
were recorded, and the experiment was repeated twice.
For the wound-healing assay, we used the Oris cell migration assay kit
(Platipus Technologies). Cells were placed, at 80% confluency, into wells
containing a round disk in the center, for creation of the detection zone. After
the cells reached confluency, theywere treatedwith 5 mg/ml ofmitomycin C for
2 hr (to block cell proliferation) and the disks were removed, thus allowing cells
to migrate to the center of the well. At 0 hr, 24 hr, 48 hr, and 72 hr time points,
images were taken at 253 and 503 magnification. The experiment was per-
formed twice with similar results. Analogous results were obtained when the
experiment was performed in the absence of mitomycin C.
For the scratching wound-healing assay, confluent HeLa cells, after mito-
mycin C treatment, were scraped away with a plastic tip in 0.8 mmwide lanes.
The cells were then incubated in DMEM with 10% FBS at normal growth
conditions, and the extent of cell migration into the wound was followed by
microscopic observation of five wounds per condition every 12 hr until 48 hr.
Images were taken at 503 magnification.
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